Literature DB >> 6723550

Epidemiology and therapy of Chlamydia trachomatis infections.

W R Bowie.   

Abstract

Chlamydia trachomatis infections are exceedingly prevalent, and can be associated with significant sequelae. The major infections are urethritis, cervicitis, salpingitis, and ocular infection. Chlamydial genital infections present as syndromes, where C. trachomatis is one of the causes of the syndrome. Because specific laboratory diagnosis of a chlamydial infection is often not available, and even if available does not exclude the concurrent presence of other pathogens, therapy should usually be directed at all the major causes of the syndrome. Thus, although C. trachomatis is readily eradicated by tetracyclines, macrolides, sulphonamides, and rifampicin, for most situations tetracyclines are the drugs of choice. Penicillins have some activity when used in multiple-dose therapy, but are not reliable for eradication of chlamydiae. Aminoglycosides, nitroimidazoles, and the newer cephalosporins have minimal or no useful activity. Seven days of tetracycline hydrochloride 500mg 4 times daily or doxycycline 100mg twice daily are the optimum regimens for uncomplicated urethritis, cervicitis (except in pregnancy), and gonorrhoea. These regimens should be extended to 10 days for epididymitis and salpingitis. Additional antimicrobials should be added to the salpingitis regimen. For chlamydial infection during pregnancy, erythromycin 500mg 4 times daily for 1 week or 250mg 4 times daily for 2 weeks should be utilised. Neonatal infection requires 2 to 3 weeks of systemic treatment with erythromycin. Inclusion conjunctivitis responds well to antimicrobials, but improved sanitation has a greater effect than antimicrobial therapy in the management of trachoma.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6723550     DOI: 10.2165/00003495-198427050-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  14 in total

1.  Antibiotic susceptibility of Chlamydia trachomatis.

Authors:  H J Blackman; C Yoneda; C R Dawson; J Schachter
Journal:  Antimicrob Agents Chemother       Date:  1977-12       Impact factor: 5.191

Review 2.  Chlamydial infections (first of three parts).

Authors:  J Schachter
Journal:  N Engl J Med       Date:  1978-02-23       Impact factor: 91.245

3.  Doxycycline treatment of chronic trachoma.

Authors:  I Hoshiwara; H B Ostler; L Hanna; F Cignetti; V R Coleman; E Jawetz
Journal:  JAMA       Date:  1973-04-09       Impact factor: 56.272

4.  Susceptibility of Chlamydia trachomatis to antibiotics in vitro and in vivo.

Authors:  G Johannisson; A Sernryd; E Lycke
Journal:  Sex Transm Dis       Date:  1979 Apr-Jun       Impact factor: 2.830

5.  Treatment of nongonococcal urethritis with rifampicin as a means of defining the role of Ureaplasma urealyticum.

Authors:  E D Coufalik; D Taylor-Robinson; G W Csonka
Journal:  Br J Vener Dis       Date:  1979-02

6.  Relative resistance to erythromycin in Chlamydia trachomatis.

Authors:  A Mourad; R L Sweet; N Sugg; J Schachter
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

7.  Erythromycin ointment for ocular prophylaxis of neonatal chlamydial infection.

Authors:  M R Hammerschlag; J W Chandler; E R Alexander; M English; W T Chiang; L Koutsky; D A Eschenbach; J R Smith
Journal:  JAMA       Date:  1980-11-21       Impact factor: 56.272

8.  Prediction of efficacy of antimicrobial agents in treatment of infections due to Chlamydia trachomatis.

Authors:  W R Bowie; C K Lee; E R Alexander
Journal:  J Infect Dis       Date:  1978-11       Impact factor: 5.226

9.  Persistence of chlamydial infection after treatment for neonatal conjunctivitis.

Authors:  E Rees; I A Tait; D Hobson; P Karayiannis; N Lee
Journal:  Arch Dis Child       Date:  1981-03       Impact factor: 3.791

10.  The antimicrobial susceptibility of Chlamydia trachomatis in cell culture.

Authors:  G L Ridgway; J M Owen; J D Oriel
Journal:  Br J Vener Dis       Date:  1978-04
View more
  7 in total

1.  In-vitro susceptibility of 400 isolates of Neisseria gonorrhoeae in Vancouver, 1982-84.

Authors:  W R Bowie; C E Shaw; D G Chan; H D Jones; W A Black
Journal:  CMAJ       Date:  1986-09-01       Impact factor: 8.262

2.  Infection by airborne Chlamydia trachomatis in a dentist cured with rifampicin after failures with tetracycline and doxycycline.

Authors:  M Midulla; D Sollecito; F Feleppa; A M Assensio; S Ilari
Journal:  Br Med J (Clin Res Ed)       Date:  1987-03-21

3.  Etiology of cervicitis and treatment with minocycline.

Authors:  W R Bowie; V Willetts; B A Binns; R C Brunham
Journal:  Can J Infect Dis       Date:  1993-03

4.  Dose-ranging study of fleroxacin for treatment of uncomplicated Chlamydia trachomatis genital infections.

Authors:  W R Bowie; V Willetts; D W Megran
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

5.  Pivampicillin compared with erythromycin for treating women with genital Chlamydia trachomatis infection.

Authors:  M Cramers; P Kaspersen; E From; B R Møller
Journal:  Genitourin Med       Date:  1988-08

6.  Treatment of genital chlamydial infection with ofloxacin.

Authors:  L Fransen; D Avonts; P Piot
Journal:  Infection       Date:  1986       Impact factor: 3.553

Review 7.  Recent advances in Chlamydia trachomatis.

Authors:  S Ladany; I Sarov
Journal:  Eur J Epidemiol       Date:  1985-12       Impact factor: 8.082

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.